CoChat

Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension

Chilton, Robert, Tikkanen, Ilkka, Hehnke, Uwe, Woerle, Hans J., Johansen, Odd Erik · 2017 · Diabetes, Obesity and Metabolism
Cited by 47

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

In the EMPA‐REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure ( SBP and DBP ) compared with placebo at week 12 in patients with type 2 diabetes mellitus ( T2DM ) and hypertension. In a post‐hoc analysis, we assessed the effect of empagliflozin on SBP and DBP using 24‐hour ambulatory BP monitoring in patients categorized as dippers (sleep‐time mean SBP ≤ 90% of awake‐time mean; n = 417) or non‐dippers (sleep‐time mean SBP > 90% of awake‐time mean; n = 350). In dippers, adjusted mean ( SE ) changes from baseline in mean 24‐hour SBP ( mm Hg ) at week 12 were −0.2 (0.7) with placebo vs −3.8 (0.6) and −3.9 (0.7) with empagliflozin 10 and 25 mg, respectively (both P < .001 vs placebo). In non‐dippers, these changes were 1.0 (0.7) with placebo vs −1.6 (0.7) with empagliflozin 10 mg ( P = .013 vs placebo) and −3.8 (0.7) with empagliflozin 25 mg ( P < .001 vs placebo). In both dippers and non‐dippers, SBP and DBP patterns over 24 hours were maintained. There were no clinically relevant changes in heart rate with empagliflozin. In conclusion, empagliflozin significantly reduced mean 24‐hour SBP compared with placebo in dippers and non‐dippers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12962

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Chilton, R., Tikkanen, I., Hehnke, U., Woerle, H. J., & Johansen, O. E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-07-07
Volume
19
Issue
11
Pages
1620-1624
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2605285548
Cited by
47
References
6
FWCI
2.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.